"label","instanceType","rationale","uuid:ID","name","id","description"
"","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","b974fed4-6e67-4215-8fd4-1c39bde09319","Study Design 1","StudyDesign_1","The main design for the study"
